← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	2,583	-9	-0.3%	$251B
2	2 Pfizer PFE $169B	2,256	+52	+2%	$185B
3	3 Merck MRK $362B	2,056	+39	+2%	$142B
4	4 AbbVie ABBV $504B	1,956	-40	-2%	$101B
5	5 Amgen AMGN $237B	1,796	+33	+2%	$104B
6	6 Bristol-Myers Squibb BMY $124B	1,729	+38	+2%	$74.8B
7	7 Gilead Sciences GILD $197B	1,528	+5	+0.3%	$79.3B
8	8 Novartis NVS $287B	1,028	+41	+4%	$22.5B
9	9 GSK GSK $98.7B	787	0	0%	$11B
10	10 Regeneron Pharmaceuticals REGN $82.4B	644	+20	+3%	$29.8B
11	11 AstraZeneca AZN $260B	545	+14	+3%	$17.4B
12	12 Incyte INCY $23B	462	+9	+2%	$13.5B
13	13 Jazz Pharmaceuticals JAZZ $13.9B	403	+27	+7%	$9.34B
14	14 DELISTED Exact Sciences EXAS	364	+16	+5%	$9.04B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	330	+35	+12%	$12.6B
16	16 Exelixis EXEL $15.6B	317	+13	+4%	$4.16B
17	17 Myriad Genetics MYGN $419M	284	+26	+10%	$3.48B
18	18 Qiagen QGEN $9.59B	246	+14	+6%	$5.43B
19	19 DELISTED Immunogen Inc IMGN	208	+10	+5%	$1.18B
20	20 Opko Health OPK $1.17B	203	-11	-5%	$526M
21	21 Halozyme HALO $13.8B	193	0	0%	$2.23B
22	CLVS 22 DELISTED Clovis Oncology, Inc. CLVS	192	-18	-9%	$1.63B
23	SPPI 23 DELISTED Spectrum Pharmaceuticals Inc SPPI	190	+10	+6%	$1.51B
24	24 DELISTED Eagle Pharmaceuticals, Inc. EGRX	189	+6	+3%	$1.07B
25	25 DELISTED Blueprint Medicines BPMC	188	+7	+4%	$3.5B